Recent News

• 11.24.2025 - Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
• 08.26.2025 - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
• 08.26.2025 - Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
• 07.23.2025 - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
• 07.23.2025 - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
• 07.17.2025 - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
• 07.17.2025 - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
• 06.17.2025 - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Recent Filings

• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.07.2025 - 8-K Current report
• 09.11.2025 - 8-K Current report
• 09.11.2025 - 8-K Current report
• 09.08.2025 - 8-K Current report
• 09.03.2025 - 8-K Current report
• 08.14.2025 - 8-K Current report
• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - DEF 14A Other definitive proxy statements
• 07.25.2025 - PRE 14A Other preliminary proxy statements